华夏恒生生物科技ETF(QDII)(159892)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-262,972,621.44 |
-769,534,744.28 |
-226,860,490.31 |
-170,864,713.84 |
利息合计 |
614,860.52 |
260,054.39 |
603,877.08 |
201,551.13 |
其中:存款利息收入 |
614,860.52 |
260,054.39 |
603,877.08 |
201,551.13 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
-126,545,902.32 |
-110,316,436.68 |
-47,433,939.01 |
-23,368,352.78 |
其中:股票投资收益 |
-165,014,737.64 |
-129,488,943.45 |
-59,123,459.21 |
-28,298,894.72 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
- |
- |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
-175,908.27 |
-175,908.27 |
-352,221.53 |
-206,546.52 |
股利收益 |
38,644,743.59 |
19,348,415.04 |
12,041,741.73 |
5,137,088.46 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
-171,129,385.05 |
-678,850,201.69 |
-217,722,710.04 |
-154,006,052.02 |
其他收入 |
32,690,698.18 |
18,218,618.01 |
37,870,500.02 |
6,376,617.89 |
费用 |
20,211,266.72 |
8,528,742.00 |
9,698,649.23 |
2,559,281.33 |
管理人报酬 |
15,225,654.76 |
6,412,771.18 |
7,236,938.32 |
1,883,039.00 |
基金托管费 |
4,567,696.41 |
1,923,831.31 |
2,171,081.49 |
564,911.66 |
销售服务费 |
- |
- |
- |
- |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
417,915.55 |
192,139.51 |
290,629.42 |
111,330.67 |
利润总额 |
-283,183,888.16 |
-778,063,486.28 |
-236,559,139.54 |
-173,423,995.17 |